Downregulation of Heparanase Expression Results in Suppression of Invasion, Migration, and Adhesion Abilities of Hepatocellular Carcinoma Cells

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2016 Feb 4

PMID 26839882

Citations 10

Authors

Xiao-Peng Chen

Jun-Sheng Luo

Ye Tian

Chen-Lin Nie

Wei Cui

Wei-Dong Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Heparanase (HPSE) is high-expressed in most malignant tumors including hepatocellular carcinoma (HCC) and promotes cancer cell invasion and migration. The aim of the study is to explore whether HPSE enhances adhesion in metastasis of HCC cells.

Methods: HPSE expressions in human HCC cells were measured with real-time RT-PCR and Western blot analysis. Four recombinant miRNA vectors pcDNATM6.2-GW/EmGFP-miR-HPSE (pmiR-HPSE) were transfected into HCCLM3 cell. HPSE expression in transfected cell was measured. The cell invasion, migration, and adhesion abilities were detected, respectively.

Results: Both HPSE mRNA and protein relative expression levels were higher in HepG2, BEL-7402, and HCCLM3 cells than those in normal hepatocyte (P < 0.05). HPSE showed highest expression level in HCCLM3 cell (P < 0.05). Transfection efficiencies of four miRNA vectors were 75%-85%. The recombinant vectors significantly decreased HPSE expression in transfected HCCLM3 cells (P < 0.01), and pmiR-HPSE-1 showed best interference effect (P < 0.05). pmiR-HPSE-1 significantly decreased the penetrated and migrating cells numbers and adherence rate of HCCLM3 cells (P < 0.05).

Conclusion: HPSE is a potentiator of cell adhesion in metastasis of HCC.

Citing Articles

Heparanase 1 Upregulation Promotes Tumor Progression and Is a Predictor of Low Survival for Oral Cancer.

Rodrigues A, Lopes-Santos L, Lacerda P, Juste M, Mariz B, Cajazeiro D Front Cell Dev Biol. 2022; 10:742213.

PMID: 36340029 PMC: 9629395. DOI: 10.3389/fcell.2022.742213.

Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis.

Nguyen T, Paone S, Chan E, Poon I, Baxter A, Thomas S Cells. 2022; 11(20).

PMID: 36291066 PMC: 9599978. DOI: 10.3390/cells11203198.

MicroRNA-219a-2-3p modulates the proliferation of thyroid cancer cells via the HPSE/cyclin D1 pathway.

Yang C, Zhang S, Chang X, Huang Y, Cui D, Liu Z Exp Ther Med. 2021; 21(6):659.

PMID: 33968189 PMC: 8097191. DOI: 10.3892/etm.2021.10091.

Heparan sulfate proteoglycans and their modification as promising anticancer targets in hepatocellular carcinoma.

Alshehri M, Alshehri M, Albalawi N, Al-Ghamdi M, Al-Gayyar M Oncol Lett. 2021; 21(2):173.

PMID: 33552290 PMC: 7798035. DOI: 10.3892/ol.2021.12434.

Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells.

Tatsumi Y, Miyake M, Shimada K, Fujii T, Hori S, Morizawa Y Int J Mol Sci. 2020; 21(11).

PMID: 32471161 PMC: 7313018. DOI: 10.3390/ijms21113789.

References

Chen G, Dang Y, Luo D, Feng Z, Tang X . Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res. 2008; 17(4):183-9. DOI: 10.3727/096504008785114138. View

Liu X, Fang H, Chen H, Jiang X, Fang D, Wang Y . An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One. 2012; 7(6):e38659. PMC: 3376136. DOI: 10.1371/journal.pone.0038659. View

Zhang L, Wang J, Tang J, Kong X, Yang J, Zheng F . VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol Biol Rep. 2011; 39(5):5085-93. PMC: 4354771. DOI: 10.1007/s11033-011-1304-2. View

Nakashima O, Kojiro M . Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg. 2001; 8(5):404-9. DOI: 10.1007/s005340100001. View

Pisano C, Vlodavsky I, Ilan N, Zunino F . The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol. 2014; 89(1):12-9. PMC: 4709407. DOI: 10.1016/j.bcp.2014.02.010. View

Shirabe K, Wakiyama S, Gion T, Motomura K, Koyanagi T, Sakamoto S . Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma--results of 152 resected cases. Hepatogastroenterology. 2008; 54(79):2084-7. View

McKenzie E . Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol. 2007; 151(1):1-14. PMC: 2012981. DOI: 10.1038/sj.bjp.0707182. View

Zheng L, Jiang G, Pu J, Mei H, Dong J, Hou X . Stable knockdown of heparanase expression in gastric cancer cells in vitro. World J Gastroenterol. 2009; 15(43):5442-8. PMC: 2778100. DOI: 10.3748/wjg.15.5442. View

Xiong Z, Lu M, Fan Y, Cao Y, Hu C, Wu Y . Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo. Int J Oncol. 2012; 40(5):1601-9. DOI: 10.3892/ijo.2012.1338. View

10.

Peng C, Zhang Z, Wu J, Lv Z, Tang J, Xie H . A critical role for ZDHHC2 in metastasis and recurrence in human hepatocellular carcinoma. Biomed Res Int. 2014; 2014:832712. PMC: 4068081. DOI: 10.1155/2014/832712. View

11.

Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L . Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J. 2003; 17(9):1015-25. DOI: 10.1096/fj.02-0773com. View

12.

Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Bitan M . Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 1999; 5(7):793-802. DOI: 10.1038/10518. View

13.

Nadir Y, Brenner B . Heparanase multiple effects in cancer. Thromb Res. 2014; 133 Suppl 2:S90-4. DOI: 10.1016/S0049-3848(14)50015-1. View

14.

Nadir Y, Brenner B . Heparanase procoagulant effects and inhibition by heparins. Thromb Res. 2010; 125 Suppl 2:S72-6. DOI: 10.1016/S0049-3848(10)70018-9. View

15.

Falanga A, Panova-Noeva M, Russo L . Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009; 22(1):49-60. DOI: 10.1016/j.beha.2008.12.009. View

16.

Chan A, Chan S, Chok K, Cheung T, Chiu D, Poon R . Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?. Liver Transpl. 2013; 19(4):411-9. DOI: 10.1002/lt.23605. View

17.

Noble S, Pasi J . Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010; 102 Suppl 1:S2-9. PMC: 3315367. DOI: 10.1038/sj.bjc.6605599. View

18.

Chen B, Chen X, Wu M, Cui W, Zhong M . Expressions of heparanase and upstream stimulatory factor in hepatocellular carcinoma. Eur J Med Res. 2014; 19:45. PMC: 4237794. DOI: 10.1186/s40001-014-0045-9. View

19.

Toyoshima M, Nakajima M . Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem. 1999; 274(34):24153-60. DOI: 10.1074/jbc.274.34.24153. View

20.

Levy-Adam F, Ilan N, Vlodavsky I . Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol. 2010; 20(3):153-60. PMC: 2941534. DOI: 10.1016/j.semcancer.2010.06.005. View